AnGes, Inc. (TYO:4563)

Market Cap	22.95B +48.4%
Revenue (ttm)	874.00M +35.9%
Net Income	-5.12B
EPS	-14.44
Shares Out	395.63M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,311,500
Average Volume	3,435,380
Open	57.00
Previous Close	58.00
Day's Range	56.00 - 59.00
52-Week Range	54.00 - 120.00
Beta	0.79
RSI	45.69
Earnings Date	Feb 10, 2026

About AnGes

AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. The company was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. AnGes, Inc. was incorporated in 1999 and is headquartered in Ibaraki, Japan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1999
• Employees: 55
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4563

Financial Performance

In 2025, AnGes's revenue was 874.00 million, an increase of 35.93% compared to the previous year's 643.00 million. Losses were -5.12 billion, -81.79% less than in 2024.